ModifiedUnitedHealthcarePolicy CSNCT0556.08

Surgery of the Shoulder (for North Carolina Only)

Defines UnitedHealthcare's medical policy for surgical procedures of the shoulder for members in North Carolina, including stance on subacromial balloon spacers for massive, irreparable rotator cuff tears.

Policy Summary

PayerUnitedHealthcare

PolicySurgery of the Shoulder (for North Carolina Only)

Policy CodePolicy CSNCT0556.08

Change TypeDocumentation language addedminor link removal

Effective DateFebruary 1, 2026

Next Review Date

Key ActionEnsure the patient's medical record contains legible documentation supporting medical necessity, including history, exam, and diagnostic results.

SourceLink

POLICY UPDATE CHANGES

Added language specifying that the patient's medical record must contain documentation that fully supports medical necessity for requested services.

Removed reference link to the guidelines titled 'Medical Records Documentation Used for Reviews'.

894Total shoulders/patients in pooled reviews

83%MCID achievement rate (Constant-Murley)

3.6%Device-related complication rate (SABS)

5%Need for salvage reverse arthroplasty

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria — Shoulder Surgery and SABS

InterQual-based surgical coverage

Covered when InterQual criteria are met for listed shoulder procedures.

InterQual-based coverage: Services such as arthroscopy, arthroscopically assisted surgery, diagnostic arthroscopy (with or without synovial biopsy), joint replacement (including removal/revision), and related shoulder procedures are medically necessary when they meet the referenced InterQual clinical pathway (CP) criteria.

Refer to InterQual CP modules: Arthroscopy or Arthroscopically Assisted Surgery, Shoulder; Arthroscopy, Diagnostic +/- Synovial Biopsy, Shoulder; Joint Replacement, Shoulder; Removal/Revision.

Subacromial Balloon Spacers (SABS)

Not medically necessary.

SABS not medically necessary: Subacromial balloon spacers (including biodegradable spacers such as InSpace) for the treatment of rotator cuff tears are considered unproven and not medically necessary due to insufficient and low-quality evidence of efficacy and inconclusive comparative effectiveness versus standard treatments.

Policy cites multiple evidence reviews (Hayes, ECRI) and notes short-term, heterogeneous studies with potential bias and limited comparative data.

Evidence- and guideline-informed coverage considerations

Coverage considerations based on evidence reviews, guideline recommendations, and FDA indication.

Efficacy evidence: Systematic reviews, RCTs, and nonrandomized studies report some improvements in pain and function for selected patients, but the overall evidence quality is poor, studies are short-term (no outcomes beyond two years reported), and comparative effectiveness versus debridement or partial repair is inconclusive.

Sources: Hayes evolving evidence review; ECRI assessment.

NICE research restriction: When debridement is a suitable option, biodegradable subacromial spacer insertion should not be used; when debridement is not suitable, spacer insertion should be used only in research (preferably randomized trials) with detailed reporting of patient selection, outcomes, and at least ~2 years of follow-up; multidisciplinary patient selection and surgeon training are recommended.follow-up >= 2 years (recommended for research)

NICE IPG 775 recommendations.

FDA indication context: FDA DeNovo classification for the InSpace Subacromial Tissue Spacer System provides an indication for use in individuals >= 65 years with massive, irreparable, full-thickness rotator cuff tears and mild-to-moderate glenohumeral osteoarthritis where shorter surgical time may be advantageous; FDA status is informational and not by itself a basis for coverage.

The policy explicitly considers the use of subacromial balloon spacers (SABS) for treatment of rotator cuff tears to be unproven and not medically necessary. This determination is based on insufficient evidence of efficacy, with published studies characterized by short follow-up, small or nonrandomized designs, heterogeneous methods, and potential industry sponsorship or author bias. Requests for SABS may be denied on this basis unless compelling, well-documented justification and evidence are provided.

The InSpace™ Subacromial Tissue Spacer System is described in the evidence base but, despite some reports of improved pain and function, current assessments conclude comparative evidence is inconclusive and of low quality; no studies demonstrate consistent long-term benefit beyond two years. Therefore SABS are excluded from coverage as unproven therapies for rotator cuff tears.

The National Institute for Health and Care Excellence (NICE) guidance (IPG 775, 2023) states that when debridement is a suitable option, biodegradable subacromial spacer insertion should not be used. If debridement is not suitable, NICE recommends spacer insertion only in the context of research, preferably randomized controlled trials, with detailed reporting of patient selection, shoulder function, pain, quality of life, and ideally with follow-up of at least 2 years.

For massive, irreparable rotator cuff tears (MIRCTs), the policy regards SABS (including the InSpace device) as not medically necessary/unproven. The published literature is limited to short-term, heterogeneous studies—some industry-associated—and lacks high-quality, consistent comparative trials showing superiority or durable benefit versus standard surgical options such as debridement or partial repair.

Because available studies do not provide robust comparative or long-term outcome data, the policy classifies SABS for MIRCTs as investigational and not covered except within a formal research context consistent with guideline recommendations.

Systematic reviews, two randomized trials, and nonrandomized studies have reported some improvements in pain and function after spacer insertion, but overall the comparative evidence is inconclusive and low quality. Reviews updated in 2024 note that while some outcomes improved from baseline, evidence for clinically meaningful improvement and superiority to debridement or partial repair is insufficient.

Key limitations include small sample sizes, heterogeneity of study designs, potential bias from industry involvement, non-blinding, and absence of outcomes beyond about 2 years. Larger, well-designed RCTs with long-term, patient-centered outcomes are needed to clarify comparative effectiveness and safety.

Coding and Billing References

Applicable CPT Codes (Reference list)CPT

23470	Arthroplasty, glenohumeral joint; hemiarthroplasty.
23472	Arthroplasty, glenohumeral joint; total shoulder (glenoid and proximal humeral replacement).
23473	Revision of total shoulder arthroplasty; humeral or glenoid component.
23474	Revision of total shoulder arthroplasty; humeral and glenoid component.
29805	Arthroscopy, shoulder, diagnostic, with or without synovial biopsy.
29806	Arthroscopy, shoulder, surgical; capsulorrhaphy.
29807	Arthroscopy, shoulder, surgical; repair of SLAP lesion.
29819	Arthroscopy, shoulder, surgical; with removal of loose body or foreign body.
29820	Arthroscopy, shoulder, surgical; synovectomy, partial.
29821	Arthroscopy, shoulder, surgical; synovectomy, complete.

1–10 of 18

1/2

Inclusion criteria (example from RCT)

Age≥ 40 years

Imaging criteriaMRI showing a full-thickness massive rotator cuff tear ≥ 5 cm involving ≥ 2 tendons

Functional examPreserved functional deltoid muscle and passive range of motion on physical examination

Pain/score thresholdVisual Analog Scale (VAS) score > 30 mm

Prior conservative therapyFailed conservative therapy for at least 4 months

Provider Actions, Authorization & Documentation

Prior Authorization

InterQual criteria required for coverage

InterQual® clinical criteria are required to determine medical necessity and coverage for shoulder procedures. Refer to the InterQual CP: Procedures for Arthroscopy or Arthroscopically Assisted Surgery, Shoulder (including adolescent criteria), Diagnostic Arthroscopy +/- Synovial Biopsy, Joint Replacement (Shoulder), and Removal/Replacement or Revision of Shoulder Joint Replacement. Coverage decisions will follow the InterQual criteria.

Documentation Required

Prior authorization / documentation note

Prior authorization may be required. Medical records documentation may be requested to assess whether the member meets the clinical criteria for coverage and to support the medical necessity of the requested service. Inclusion of procedure or diagnosis codes in this policy is for reference and does not guarantee coverage or payment.

Medical records may be requested as part of prior authorization or claim review.

Background — MIRCT and Treatment Options

Massive, irreparable rotator cuff tears (MIRCTs) are full-thickness tears often involving multiple tendons and not amenable to complete repair. Surgical management options span from arthroscopic debridement and partial repair to tendon transfers, superior capsular reconstruction, and reverse total shoulder arthroplasty. Investigational approaches include biodegradable subacromial balloon spacers intended to act as a temporary spacer that biodegrades over roughly 12 months and may reduce friction and improve function.

The evidence base for spacer devices is largely short-term and heterogeneous; because of limited comparative data and potential biases in available studies, spacers remain an investigational option in the context of clinical research rather than a standard surgical alternative for MIRCTs.

Definitions and Device Descriptions

InSpace Subacromial Tissue Spacer System — device description

Device nameInSpace Subacromial Tissue Spacer System (Stryker)

TypeMinimally invasive, biodegradable balloon spacer placed in the subacromial space

Intended effectActs as a spacer to eliminate friction between the acromion and humeral head/rotator cuff to restore function and reduce pain

Biodegradation timeframeDesigned to biodegrade over approximately 12 months

Implant characteristicsPreserves musculoskeletal and bone tissues; does not require anchors or a permanent implant (manufacturer claim)

Massive, irreparable rotator cuff tear (MIRCT) — trial definition